Abstract
Introduction: Skull base chordomas are aggressive tumors with a propensity for recurrence and local progression. Even with standard of care (SoC) treatment including maximal safe surgical resection and proton radiotherapy, 5-year recurrence rates are variable (19–54%). This high disease recurrence/progression rate, alongside chordoma's local aggressive characteristics, correlates with an increased morbidity and mortality.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have